

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.


Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

(A)



(B)





FIG. 1

ATTACHMENTS OF LIGANDS THROUGH PRIMER REGION

(A)



(B)




FIG. 2

ATTACHMENT OF LIGANDS BY INCORPORATION OF
MODIFIED NUCLEOTIDE PRECURSORS




FIG. 3

Incorporation of Ligands through Modified Ribonucleotides




FIG. 4

Attachment of Ligands through a 3' tail





FIG. 5

Preparation of Gapped Circle



6/51

(A)



(B)




FIG. 6

Attachment of Ligands through hybridization to a 3' tail




FIG. 7

RNA with Ligands on Primer




FIG. 8
RNA with Ligands on Primer (Continued)





FIG. 9


RNA with Ligands on Multiple Primers




10/51




Reverse Transcriptase catalyzes extensions from modified primers as well as displacements of strands




+




+




Elimination of RNA template by RNase H






+



+



Secondary priming by tRNA at L'M' site and extension by Reverse Transcriptase



+




FIG. 10

RNA with Ligands on Multiple Primers (Continued)





FIG. 11

Single-stranded DNA with attached Ligands

(A)

Presence of a single tRNA primer site



(B)

Presence of multiple tRNA primer sites




FIG. 12

Single-stranded DNA with attached Ligands (continued)



13/51




FIG. 13

Linear Double-stranded DNA with attached Moieties on each strand




FIG. 14
Enhanced Delivery of Retroviral Vector
to Haematopoietic Stem Cell

NOV 21 2003
PATENT & TRADEMARK OFFICE
C&C

15/51





FIG. 15
Enhanced Delivery of Vector
DNA to Haematopoietic Stem Cell

OI - JC&W
NOV 21 2003
PATENT & TRADEMARK OFFICE

16/51

(A)

Dimeric Antibody formed from complete Antibody pieces



(B)

Dimeric Antibody formed from F(ab') fragments




FIG. 16

Covalent Attachment of vector DNA to Dimeric Antibody



17/51




FIG. 17

Covalent attachment of Modified DNA
to a Monovalent Antibody




FIG. 18

Modified DNA used as a Binder

U.S. PAT. & TRADEMARK OFFICE
NOV 21 2003
SEARCHED & INDEXED
MAILED & TRADEMARK OFFICE

19/51




FIG. 19

Synthetic Steps for Creation of Antibodies
With Nucleic Acid Moieties Attached



20/51




FIG. 20
Continuation of Synthetic Steps

NOV 21 2003
PATENT & TRADEMARK OFFICE

21/51




FIG. 21

Enhanced Binding of Antibodies to Antigens by Multimerization



22/51




FIG. 22
High Affinity Multi-Insulin Soluble Complex




FIG. 23
Multimerization of Insulin molecules by hybridization to discrete Sequences



24/51

Intron insertion site

(A)

----TGCTCTCTAAGGGTCTACTC----
----ACGAGAGATTCCCAGATGAG----

T7 RNA Polymerase Sequence

Splice Donor Site

Splice Acceptor Site

(B)



----CTCTAAGGTAAATAT - - - - - TGTATTTAGATTCAA----
----GAGATTCCATTTATA - - - - - ACATAAAATCTAAGTT----

SV40 Intron Sequence

(C)

----TGCTCTCTAAGGTAAATAT - - - - - TGTATTTAGGGTCTACTC----
----ACGAGAGATTCCATTTATA - - - - - ACATAAAATCCCAGATGAG----

Insertion of SV40 Intron into polymerase coding sequence

Splice Donor Site

Splice Acceptor Site

(D)



----UGCUCUCUAAGGUAAAUAU - - - - - UGUAUUUUAGGGUCUACUC----

mRNA transcript containing intron

(E)

----UGCUCUCUAAGGGUCUACUC---

mRNA transcript after splicing has normal T7 Sequence

FIG. 24


Fusion of Intron into T7 RNA Polymerase Coding Sequence

25/51


NOV 21 2003
CIR 5 JC&W
U.S. TRADEMARK OFFICE

(A)

Normal T7 RNA polymerase coding sequence




Synthesis of fragments by PCR Amplification of T7 or SV40 templates



(B)

Fusion of PCR fragments together in eucaryotic expression vector



(C)

Introduction of cassette with AS directed from T7 promoter





FIG. 25
Construction of T7 Expression Vector

(A) Synthesis of pieces



(B) Oligomers used for synthesis

TSP-1	GGA ATT CGT CTC GAG CTC TGA TCA CCA CCA TGG ACA CGA TTA ACA TCG C
TSP-2	GAC TAG TTG GTC TCG TCT CTT TTT TGG AGG AGT GTC GTT CTT AGC GAT GTT AAT C
TSP 3	GGA ATT CGT CTC GGA GAA AGG TAA AAT TCT TCT ACA TCG AAC TGG C
TSP-4	GAC TAG TGG TCT CCC CTT AGA GAG CAT GTC AGC
TSP-5	GGA ATT CGG TCT CGG GTC TAC TCG GTG GCG AGG
TSP-6	GAC TAG TCG TTA CGC GAA CGC AAA GTC
INT-1	GGA ATT CGT CTC TAA GGT AAA TAT AAA ATT TTT AAG
INT-2	GAC TAG TCG TCT CTG ACC CTA AAA TAC ACA AAC AAT TAG A

FIG. 26

Synthesis of Pieces for Construction of
T7 RNA Polymerase with Intron



TSP1 Annealing of TSP1 with TSP2

Extension of TSP1/TSP2 by polymerase

5' GG AAT TCG TCT CGA GCT CTG ATC ACC ATG GAC ATT AAC ATC GCT AAG AAC GAC ACT CCT CCA AAA AAG AGA CGA GAC CAA CTA GTC 3'

Digestion of TSP1/TSP2 product with Bsa I

Digestion of 15¹I/15² product with λ exonuclease 1

Diagnosis of PCB #1 alone ($n=1$) with BsmB I

Ligation of *Bsa* I digested TS1/TS2 product to *BsmB* I digested PCR#1 clone

5' GG AAT TCG TCT CGA GCT CTG ATC ACC ACC ATG GAC ACT AAC ATC GCT AAG AAC GAC ACT CCT CCA AAA AAG AGA AAG GTA AAA TTC
 3' CC TTA AGC AGA GCT CGA GAC GTA TGG TAC CTG TGC TAA TTG TAG CGA TTC TTG CTG TGA GGT TTT TTC TCT TGT CAT TTT AAG
 TCT GAC ATC GAA CTG GC-----
 AGA GTC TAC CCT GAC GCA

EIG 27

Formation of Nuclear Localisation Signal by Fusion of TSP1/TSP2 Product to Clone with PCR #1 product



28/51

Wild Type T7 nucleic and amino acid sequence

ATG GAC ACG ATT AAC ATC GCT AAG AAC GAC TTC TCT GAC ATC GAA CTG GC -----
TAC CTG TGC TAA TTG TAG CGA TTC TTG CTG AAG AGA CTT GAC CG-----
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Modified T7 nucleic and amino acid sequence
with Nuclear Localisation Signal (NLS) insertion

ATG GAC ACG ATT AAC ATC GCT AAG AAC GAC ACT CCT CCA AAA AAG AGA AAG GAA TTC TCT GAC ATC GAA CTG GC-----
TAC CTG TGC TAA TTG TAG CGA TTC TTG CTG TGA GGA GGT TTT TTC CAT TTT AAG AGA CTG TAG CTT GAC CG-----
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

FIG. 28

Comparison of the 5' ends of the Nucleotide Sequences of Wild Type
and Modified T7 RNA Polymerase



29/51




FIG. 29

Fusion of PCR Pieces to Construct
T7 RNA Polymerase with an Intron

(A)

Oligomers

HTA-1 GAT CAT TAG ACC AGA TCT GAG CCT GGG AGC TCT CTG GCT AAC TAG GGA ACC CAC TGC TTA AGC CTC AAG
HTA-2 GAT CCT TGA GGC TTA AGC AGT GGG TTC CCT AGT TAG CCA GAG AGC TCC CAG GCT CAG ATC TGG TCT AAT

HTB-1 GAT CAC CTT AGG CTC TCC TAT GGC AGG AAG CGG AGA CAG CGA CGA AGA CCT CCT CAA G
HTB-2 GAT CCT TGA GGA GGT CTT CGT CGC TGT CTC CGC TTC CTG CCA TAG GAG AGC CTA AGG T

HTC-1 GAT CAT AGT GAA TAG AGT TAG GCA GGG ATA CTC ACC ATT ATC GGT TCA GAC CCA CCT CCC AG
HTC-2 GAT CCT GGG AGG TGG GTC TGA AAC GAT AAT GGT GAG TAT CCC TGC CTA ACT CTA TTC ACT AT

TER-1 AAT CTA GAG CTA ACA AAG CCC GAA AGG AAG
TER-2 TTC TGC AGA TAT AGT TCC TCC TTT CAG C

(B)

Cloning of AS and Terminator sequences
into vector with T7 Promoter




FIG. 30

Insertion of Anti-Sense Sequences into
T7 Directed Transcription Units




FIG. 31

Construct with t7 RNA polymerase and Anti-Sense directed from a T7 Promoter



32/51

A) Oligomers for introduction of T7 signals and polylinker

PL-1 TCG AGC CAT GGC TTA AGG ATC CGT ACG TCC GGA GCT AGC GGG CCC ATC GAT ACT
 AGT TAA ATG CAG ATC T

PL-2 CTA GAG ATC TGC ATT TAA CTA GTA TCG ATG GGC CCG CTA GCT CCG GAC GTA CGG
 ATC CTT AAG CCA TGG C




FIG. 32

Introduction of Poly-Linker for Creation of Protein Expression Vector




FIG. 33

Final steps for construction of Expression Vector





FIG. 34

Construct that produces single-stranded Anti-Sense DNA




35/51


(Structure 34e)




Nicking by RNase H




Extension by RT and digestion by RNase H




(Structure 35h)




(Structure 35i)



(Structure 35j)




(Structure 35k)



Extension by RT and displacement generates
Single-stranded DNA and a mostly Double-stranded
DNA molecule

FIG. 35
Continuation of Process from Figure 34



In this example, A B C is a promoter sequence, directing transcription off of these double-stranded DNA products to create RNA transcripts with varying amounts of double-stranded character. Furthermore, the single-stranded loop segment (D to D') of the transcript codes for anti-sense sequences

FIG. 36

Construct that produces RNA that is Reverse Transcribed to create Secondary DNA Constructs capable of directing transcription



37/51





FIG. 37

Construct which Propagates a Double Hairpin Production Center



38/51



In this Example, the sequence F' E' D' is a promoter, the sequence GHJK is an Anti-Sense sequence and X Y Z is a poly A signal

FIG. 38

Continuation of process from Figure 37




FIG. 39

Construct which propagates a Production Center capable of Inducible Suicide




FIG. 40

Use of tRNA primers to create a DNA construct for secondary production of transcripts



41/51






FIG. 41

Excision of sequences from U1 Transcript Region
and Replacement with Novel Sequences

(A) Anti-sense oligomers

HVA-1 GAT CCG GAT TGA GGC TTA AGC AGT GGG TTC CCT AGT TAG CCA GAG AGC TCC CAG GCT CAG ATC TGG TCT AAT
 HVA-2 CCG GAT TAG ACC AGA TCT GAG CCT GGG AGC TCT CTG GCT AAC TAG GGA ACC CAC TGC TTA AGC CTC AAT CCG
 HVB-1 GAT CCG GAC CTT GAG GAG GTC TTC GTC GCT GTC TCC GCT TCT TCC TGC CAT AGG AGA GCC TAA GGT
 HVB-2 CCG GAC CTT AGG CTC TCC TAT GGC AGG AAG CGG AGA CAG CGA CGA AGA CCT CCT CAA GGT CCG
 HVC-1 GAT CCG GAT GGG AGG TGG GTC TGA AAC GAT AAT GGT GAG TAT CCC TGC CTA ACT CTA TTC ACT AT
 HVC-2 CCG GAT AGT GAA TAG AGT TAG GCA GGG ATA CTC ACC ATT ATC GTT TCA GAC CCA CCT CCC ATC CG
 HVD-1 GAT CAG CAT GCC TGC AGG TCG ACT CTA GAC CCG GGT ACC GAG CTC GCC CTA TAG TGA GTC GTA TTA T
 HVD-2 CCG GAT AAT ACG ACT CAC TAT AGG GCG AGC TCG GTA CCC GGG TCT AGA GTC GAC CTG CAG GCA TGC T

(B) Replacement of U1 sequences with HIV Anti-sense sequences




FIG. 42
Insertion of Anti-Sense Sequences into U1 Operons




FIG. 43

Predicted secondary structures for U1
Transcripts with Anti-sense Substitutions




FIG. 44

Construction of U1 Multiple Operon Clone





FIG. 45
Construction of T7 Triple Operon



46/51

pNDU1(A,B,C)

Triple U1 Operon Construct with HIV Anti-Sense



TRI 101

Triple T7 Operon Construct with HIV Anti-Sense




FIG. 46

Structures of Triple Operon Constructs
from Figures 44 and 45




FIG. 47

Construction of Multiple T7 Operons in Vector coding for T7 RNA Polymerase




FIG. 48

Flow cytometry data measuring binding of
anti-CD4+ antibody to HIV resistant U037 cells

15750 U.S. PTO



112103

49/51




FIG. 49

PCR amplification of gag region
indicating absence of HIV in
viral resistant cell line (2.10.16)
after challenge




FIG. 50

Clone with target-lacZ fusion will have reduced expression of lacZ after transfection by HIV Anti-sense construct



51/51

(A)

Enzyme activity as expressed by A_{420} readings
in extracts prepared from

	2.5×10^4 cells	5×10^4 cells	1.0×10^5 cells
U 937 (untransfected)	0.018	0.023	0.034
U 937 (HIV A clone)	0.154	0.277	0.566
U937 (HIV A/Anti-A)	0.010	0.017	0.027
U 937 (HIV A/Anti-ABC)	0.013	0.021	0.035
U 937 (HIV A/Null DNA)	0.120	0.212	0.337

(B)

Expression of Beta-galactosidase activity by In situ assay:

U 937 (untransfected)	no blue spots in cells
U 937 (HIV A clone)	blue spots in cells
U 937 (HIV A/Anti A)	no blue spots in cells
U 937 (HIV A/Anti ABC)	no blue spots in cells
U 937 (HIV A/Null DNA)	blue spots in cells

FIG. 51

Expression of Beta-galactosidase activity
in extracts